AWH Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States...

Stats
Today's Volume	17 402.00
Average Volume	23 884.00
Market Cap	41.06M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.360 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.840
ATR14	$0.0420 (1.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Milligan Sandra	Buy	0
2024-02-15	Sandford Nicole	Buy	30 000	Employee stock option (right to buy)
2024-02-14	Hombeck Torsten	Buy	20 000	Employee stock option (right to buy)
2024-02-14	Merchant Minh Hoang	Buy	11 000	Employee stock option (right to buy)
2024-01-26	Sandford Nicole	Buy	2 400	Common Stock

INSIDER POWER
97.16
Last 89 transactions
Buy: 4 429 531 \| Sell: 195 424

Aspira Women's Health Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aspira Women's Health Financials

Annual	2023
Revenue:	$9.15M
Gross Profit:	$5.26M (57.48 %)
EPS:	$-1.810

FY	2023
Revenue:	$9.15M
Gross Profit:	$5.26M (57.48 %)
EPS:	$-1.810

FY	2022
Revenue:	$8.18M
Gross Profit:	$4.32M (52.77 %)
EPS:	$-41.66

FY	2021
Revenue:	$6.81M
Gross Profit:	$3.06M (44.95 %)
EPS:	$-0.280

Financial Reports:

No articles found.

Aspira Women's Health

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.